0% 10% 20% 30% 40% 50% 1 2 3 4 5 6 7 8 9 10 11 Tarcocimab BRVO Tarcocimab All RVO Aflibercept BRVO Aflibercept All RVO Number of injections through Year 1 Proportion of subjects 78% received ≤5 doses with Zenkuda 93% received ≥ 6 doses with aflibercept Zenkuda in Retinal Vein Occlusion: Demonstrated high efficacy and industry-leading durability in the Phase 3 BEACON study RVO: retinal vein occlusion; BRVO: branched retinal vein occlusion; 1. Durability interval calculated based on patients that received no injections (46%) or 1 injection (29%) over the second 6 months of Year 1. Zenkuda: Number of doses in the second 6 months of Year 1 0-1 doses 2 doses 18% 4-6 doses: 2% 3 doses: 5% 6-month durability 75% 1 Primary Endpoint 6-month Durability Phase 3 BEACON 24